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Abstract
Background: Mutations in the mitochondrial tyrosyl-tRNA synthetase (YARS2) gene have previously been identified
as a cause of the tissue specific mitochondrial respiratory chain (RC) disorder, Myopathy, Lactic Acidosis, Sideroblastic
Anaemia (MLASA). In this study, a cohort of patients with a mitochondrial RC disorder for who anaemia was a feature,
were screened for mutations in YARS2.
Methods: Twelve patients were screened for YARS2 mutations by Sanger sequencing. Clinical data were compared.
Functional assays were performed to confirm the pathogenicity of the novel mutations and to investigate tissue
specific effects.
Results: PathogenicYARS2 mutations were identified in three of twelve patients screened. Two patients were found to
be homozygous for the previously reported p.Phe52Leu mutation, one severely and one mildly affected. These patients
had different mtDNA haplogroups which may contribute to the observed phenotypic variability. A mildly affected
patient was a compound heterozygote for two novel YARS2 mutations, p.Gly191Asp and p.Arg360X. The p.Gly191Asp
mutation resulted in a 38-fold loss in YARS2 catalytic efficiency and the p.Arg360X mutation did not produce a stable
protein. The p.Phe52Leu and p.Gly191Asp/p.Arg360X mutations resulted in more severe RC deficiency of complexes I, III
and IV in muscle cells compared to fibroblasts, but had relatively normal YARS2 protein levels. The muscle-specific RC
deficiency can be related to the increased requirement for RC complexes in muscle. There was also a failure of mtDNA
proliferation upon myogenesis in patient cells which may compound the RC defect. Patient muscle had increased levels
of PGC1-α and TFAM suggesting mitochondrial biogenesis was activated as a potential compensatory mechanism.
Conclusion: In this study we have identified novel YARS2 mutations and noted marked phenotypic variability among
YARS2 MLASA patients, with phenotypes ranging from mild to lethal, and we suggest that the background mtDNA
haplotype may be contributing to the phenotypic variability. These findings have implications for diagnosis and
prognostication of the MLASA and related phenotypes.
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Background
Mitochondrial respiratory chain (RC) disorders are among
the most prevalent inborn errors of metabolism with an
incidence of ~1:8000 births [1]. They are a clinically het-
erogeneous group of disorders caused by mutations in ei-
ther mitochondrial or nuclear DNA [2]. Mitochondrial RC
function requires the coordinated expression of both
mitochondrial and nuclear encoded genes, to supply the
majority of cellular energy demands. The respiratory
capacity is regulated depending on the energy require-
ments of the tissue and prevailing metabolic conditions
[3]. Compensatory mechanisms, such as mitochondrial
proliferation, may be activated in cases of mitochon-
drial RC dysfunction [4]. The dynamic nature of the
mitochondrial RC may be one of the contributing fac-
tors to the tissue-specific manifestations, and inter- and
intra-familial phenotypic variability that is frequently
observed in mitochondrial RC disorders. These factors
further complicate diagnosis and prognostication [5].
Many of the mitochondrial RC disorders result from
genetic defects that impair mitochondrial protein syn-
thesis, with mutations reported in mitochondrial tRNAs,
aminoacyl-tRNA synthetases, elongation factors and ribo-
somal proteins [6]. Curiously, these do not result in the
same phenotype, but a spectrum of disorders. Even muta-
tions within the mitochondrial aminoacyl-tRNA synthe-
tase (ARS2) family of proteins, which are responsible for
connecting mitochondrially located tRNAs with their
cognate amino acids, result in different clinical pheno-
types with discrete tissue-specific involvement. DARS2
[7], EARS2 [8] and MARS2 [9] mutations cause leu-
koencephalopathy; each with other gene-specific CNS
involvement; RARS2 mutations result in pontocerebellar
hypoplasia [10]; HARS2 and LARS2 mutations result in
ovarian dysgenesis and sensorineural hearing loss [11,12];
AARS2 mutations cause infantile cardiomyopathy [13];
SARS2 mutations cause hyperuricemia, pulmonary hyper-
tension, renal failure in infancy and alkalosis [14]; FARS2
mutations cause mitochondrial encephalopathy [15]; and
we recently identified a YARS2 mutation as a novel cause
of a mitochondrial RC disorder characterised by a skeletal
myopathy, lactic acidosis and sideroblastic anaemia
(MLASA) [16]. MLASA has also been associated with
mutations in PUS1 [17]. The reason for the diverse
range of symptoms resulting from mutations in mito-
chondrial aminoacyl-tRNA synthetases is unclear, how-
ever several cytoplasmic aminoacyl-tRNA synthetases have
been found to have additional functions besides their role
in protein synthesis, and it may be that other functions of
mitochondrial aminoacyl-tRNA synthetases influence the
distinct pathogenesis of aminoacyl-tRNA synthetase dis-
orders [18]. The tissues affected by mitochondrial RC
disorders are commonly those with higher energy re-
quirements and/or those with greater sensitivity to
mitochondrial dysfunction, which cannot be function-
ally sustained in the face of compromised mitochon-
drial RC output. However, this does not explain why
different patients may manifest abnormalities of brain,
heart or skeletal muscle function for example, but not
all three of these energy-demanding tissues. It is clear
that the pathogenesis of mitochondrial RC disorders is
more complicated than the simple concept of metabolic
demands, and a better understanding of the basis for
tissue-specific manifestations and phenotypic variabil-
ity is needed.
In this study we further define the clinical spectrum as-
sociated with YARS2 mutations identified in three pro-
bands. We identified the p.Phe52Leu mutation, originally
described as a likely founder mutation [16], in two other
families. Considerable phenotypic variability was observed
among the p.Phe52Leu YARS2 patients, which has im-
portant implications for diagnosis. We propose that this
phenotypic variability may in part be due to differences in
mtDNA haplogroups among patients. In addition, we
found two novel YARS2 mutations in a patient and de-
fined their biochemical characteristics and tRNATyr ami-
noacylation dysfunction. We also examined the basis for
the tissue-specific manifestation of YARS2 mitochondrial
myopathy.
Methods
Clinical information
The Human Research Ethics Committee of the Chil-
dren’s Hospital at Westmead approved this research.
A cohort of 12 patients was selected for YARS2 scree-
ning. Selection criteria included presence of anaemia,
with or without lactic acidosis (10/12 patients had lac-
tic acidosis), with or without skeletal myopathy (6/12
patients displayed myopathy/hypotonia), and a demon-
strated respiratory chain enzyme deficiency. Nine of
the 12 patients screened were of French origin, one was
Italian and the other two were Australians of Lebanese
origin, unrelated to the two original families for which
a YARS2 mutation was previously described [16]. Cli-
nical histories for patients for whom we identified
pathogenic YARS2 mutations are given below (patients
4, 5 & 6) and previously reported cases are reviewed
(patients 1, 2 & 3). Clinical features of the other pa-
tients are presented in Additional file 1.
Patient 1 and 2 are siblings of consanguineous parents
and have been described previously [16]. Briefly, within the
first 3 months of life P1 developed transfusion dependent
sideroblastic anaemia and had persistent lactic acidaemia
and hypertrophic cardiomyopathy. The cardiomyopathy
spontaneously resolved. He had progressive exercise toler-
ance and at 17 years he developed dysphagia and acute re-
spiratory difficulties and succumbed at 18 years of age. P2
also developed transfusion dependent sideroblastic anaemia
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in infancy and had persistent lactic acidaemia and pro-
gressive muscle weakness, similar to P1. At 15 years she
developed dysphagia and had a gastrostomy inserted. Re-
markably, at 17 years of age P2 showed improved muscle
strength and stamina, and no longer required blood trans-
fusions (previously being given every six weeks). She is
currently 20 years old. Patient 3 [16], born to consanguin-
eous parents, had delayed motor milestones and devel-
oped sideroblastic anaemia at 7 years, as well as lactic
acidaemia. Her parents refused to allow her to have blood
transfusions and she was treated with complementary
therapies. At 24 years she had a mild skeletal myopathy,
anaemia and mild peripheral muscle weakness.
Patient 4, the second child of non-consanguineous par-
ents of Lebanese origin, is not known to be related to the
other patients described here. There were no antenatal
concerns. She was born at term by normal delivery with
good Apgar scores. She had low birth weight of 2.7 kg but
there were no immediate postnatal problems. She fed well
by formula and was gaining weight at home.
There is a family history of a maternal aunt with sickle
cell anaemia. The parents have a healthy 3-year old daugh-
ter, and there is a history of a prior fetal demise at 12 weeks
gestation.
The proband presented at 8 weeks of age in acute hy-
potensive shock needing cardiopulmonary resuscitation
following a few days of rhinorrhoea, loose stools and as-
sociated lethargy and feeding difficulties. A venous
blood gas at the time of arrest showed pH 6.56, bicar-
bonate of 4.2 mmol/L, BE −28.8, anion gap of 30 and
lactate of 27 mmol/L (normal range 0.7 – 2.0). A CT
scan of the brain was normal. Urine metabolic screening
showed increased lactate and ketones. Plasma amino
acids, triglycerides, free fatty acids, uric acid, blood ammo-
nium and serum transferrin isoforms were normal. There
was a slightly low plasma total carnitine level noted.
She had associated multisystem problems. These in-
cluded significant concentric left ventricular hypertrophy
with altered echotexture, and abnormal diastolic func-
tion. She had an initial mild pericardial effusion which
later required pericardial drainage. She also had hepato-
megaly with raised transaminases and coagulopathy. She
had possible seizures, managed with anticonvulsants. A
subsequent MRI/MRS of the brain showed cerebral atro-
phy with normal spectroscopy and no lactate peak.
She had anaemia, with the lowest haemoglobin being
42 g/L, and required intermittent packed cell transfu-
sions. Bone marrow aspirate showed reduced erythropoi-
esis with prominent red cell vacuolation in the red cell
precursors and ringed sideroblasts. There was no evi-
dence of a storage disorder on bone marrow biopsy.
She did not tolerate weaning from mechanical ventila-
tion. Impaired cardiac output in conjunction with the
above associated issues led to eventual decision for
withdrawal of active intensive care. She succumbed at
three months of age.
Subsequent to identification of the p.Phe52Leu YARS2
mutation, they have had two pregnancies which under-
went prenatal testing, and were then terminated as both
were found to be homozygous for the mutation.
Patient 5 is one of four siblings to non-consanguineous
Lebanese parents (although they are from the same village
in Northern Lebanon). Her sister was diagnosed with side-
roblastic anaemia in Lebanon in her mid 20s and had been
transfusion dependent for around 10 years. She ultimately
died of cirrhosis induced by iron overload 10 years after
commencing blood transfusions. This individual was re-
ported to be an otherwise fairly healthy young woman
without any other medical concerns.
Patient 5 was noted to be anaemic at the age of 23. An
initial bone marrow performed in Lebanon reportedly
showed a form of refractory anaemia for which she had
four erythropoietin injections. Subsequently, she returned
to Australia and a second bone marrow aspirate four years
later demonstrated ringed sideroblasts. At that time, her
lactate was elevated at 3.24 mmol/L with a pyruvate of
0.13 mmol/L. On review a year later, her lactate was
5.10 mmol/L and haemoglobin was low at 104 g/L. Crea-
tine kinase was 30 U/L, at the lower end of the normal
range.
Patient 5 was found to have scoliosis at the age of
11 years, and she went on to have titanium rods inserted
which were subsequently removed secondary to infec-
tion. She has subsequently had a spinal fusion. She also
has endometriosis.
Her 6-minute walk time was reduced at 353 m. Her
pulmonary function tests demonstrated a mild restrictive
defect with the FVC of 70% predicted and FEV1 of 70%
predicted; the Diffusing lung capacity for carbon monox-
ide (DLCO) was normal. Her ECG and echocardiog-
raphy were also normal.
On examination, there was no organomegaly, and her
cardiovascular and respiratory examination was normal.
She had a long, well-healed scar over her spine, with a
slight residual right thoracic scoliosis. She had subtle bilat-
eral hip flexor weakness, but her power otherwise was in-
tact. Deep tendon reflexes and sensation were normal.
There were no problems with gait or balance. Intelligence
was normal.
Patient 6, the child of non-consanguineous parents of
French origin required blood transfusion for sideroblas-
tic anaemia in the first year of life, which resolved spon-
taneously. A bone marrow examination during the first
year of life showed the presence of megakaryocytes,
signs of erythroblastic dysplasia, and an excess of sidero-
blasts. A partial deficiency in complex IV was detected
in lymphocytes (muscle biopsies were not performed),
and abnormal assembly of RC complexes I, III, IV and V
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were observed on Blue Native-PAGE of fibroblasts. At
3 years of age there was a discrete thickening of the myo-
cardium, which normalised by age 5 years. No skeletal
myopathy was present, but she had nystagmus and stra-
bismus. Liver function tests were normal. Mild but per-
manent lactic acidaemia (3 mmol/L) was found at 5 years.
Lactic acidaemia was also present at 6 years and she re-
ported fatigue on prolonged walking or climbing stairs, to-
gether with leg pain and muscle weakness. There was no
evidence of anaemia. Intelligence was normal.
YARS2, PUS1 and mtDNA sequencing
All YARS2 and PUS1 coding exons were PCR amplified
from gDNA and Sanger DNA sequencing performed by
Macrogen (Korea). mtDNA from p.Phe52Leu YARS2 pa-
tients was sequenced at the Lotterywest State Biomedical
Facility Genomics, Royal Perth Hospital. mtDNA hap-
logroups were assigned using Haplofind [19].
Cloning and aminoacylation assays
Recombinant YARS2 mutant proteins were generated to
assess their tyrosylation activity. Recombinant wild-type
and YARS2 variants were cloned, expressed and purified
from E. coli as previously described [20]. In vitro tRNATyr
aminoacylation assays were performed using previously
described methods [20]. Apparent kinetic parameters were
determined from Lineweaver-Burk plots in the presence
of 5 to 27 nM YARS2 (depending on the variant) and na-
tive E. coli tRNATyr (Sigma), with concentrations ranging
from 0.28 to 2.1 μM. Experimental errors for kcat and Km
varied at most by 20%. Numerical values are averages of at
least two independent experiments.
Native and Myo-D forced myogenesis
Primary patient and control fibroblast cell lines were
routinely cultured in DMEM: F12 (Life Sciences) con-
taining 20% Amniomax (Life Sciences) and 10% heat
inactivated fetal bovine serum (FBS; In Vitro Technolo-
gies), penicillin (50 μg/ml) and streptomycin (50 μg/ml;
Life Sciences) and primary myoblast cell lines were cul-
tured in DMEM: F12, 20% Amniomax, 20% FBS, in a
humidified incubator containing 5% CO2 and maintained
at 37°C. Fibroblasts were transduced and differentiated
using a lentiviral MyoD vector as previously described
[21], except that cells were seeded onto plates coated with
0.15 mg/ml rat tail collagen (BD Biosciences). Myoblasts
were differentiated in the same media as described for
fibroblast transdifferentiation. Cells were harvested at day
6 of differentiation for enzyme assays, immunoblotting or
DNA extraction.
RC enzyme assays
Respiratory chain enzyme activities were determined as
previously described [22].
Immunoblotting
Immunoblotting was as previously described [16], with the
following modifications. Membranes were probed with
1:500 anti-OXPHOS (Abcam) for 2 h at room temperature
or with 1:500 anti-YARS2 (N-terminal, Abgent), 1:10000
anti-porin (Abcam), 1:1000 anti-mitofilin (Abcam),
1:500000 anti-α-actinin-2 (a generous gift to the INMR
from Prof Alan Beggs, Harvard Medical School, Boston
Children’s Hospital, Division of Genetics), 1:500 anti-
PGC1-α (Sigma) or 1:500 anti-TFAM (Abcam) overnight
at 4°C. Densitometry was performed as previously de-
scribed [16] and protein levels were normalised to porin
protein levels.
DNA extraction
DNA was isolated from patient fibroblast cell pellets and
skeletal muscle tissues and sex- and age-matched con-
trols using a QIAamp DNA mini kit (QIAGEN). Tissues
were homogenized using a TissueRuptor (QIAGEN).
Samples were treated with RNase A (QIAGEN).
mtDNA/nDNA determination by qPCR
A mitochondrial encoded gene (ND1) was quantified rela-
tive to a single copy number nuclear encoded gene (β2M)
[23] to determine the mtDNA content in patient and con-
trol myoblasts, myotubes and muscle. These genes were
amplified in separate reactions containing 40 ng total DNA,
1 Unit of Immolase™ DNA Polymerase (Bioline), and a final
concentration of 1.5 mM MgCl2, 500 pM of each primer,
2% DMSO and 1 M betaine. Standard curves were gener-
ated by amplifying known amounts of a pTOPO2.1/B2M
or pTOPO2.1/ND1 plasmid. The cycle conditions were:
95°C for 12 minutes, (95°C for 15 s, 60°C for 15 s, 72°C for
20 s) × 35 cycles. Primer sequences were (5' to 3'): ND1_F –
CATAAAACTCTTCACCAAAGAGCC; ND1_R – GGGG
TTCATAGTAGAAGAGCGA; β2M_F – TGCTGTCTCC
ATGTTTGATGTATCT; β2M_R – TCTCTGCTCCCCAC
CTCTAAGT.
Statistical analyses
Generalised linear models for univariate analysis (SPSS
v.19, IBM) were used to assess the effect of cell type
(fibroblast, forced myotube), sample (patient P2, patient
P6, control) and their interaction with normalised Com-
plex IV activity and normalised Complex IV/CS activity.
Generalised linear models for univariate analysis were
also used to assess the effect of cell type (myoblast, myo-
tube), sample (patient P2, control) and their interaction
with relative mtDNA/nDNA. Where there was a signifi-
cant interaction between cell type and sample, effects
were analysed independently. No adjustments were
made for multiple statistical analyses. An independent
sample t-test (SPSS v.19, IBM) was used to test for
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differences in relative mtDNA/nDNA between patient
and control muscle.
Results
Additional p.Phe52Leu YARS2 patients display marked
clinical variability
We have previously identified a p.Phe52Leu YARS2 mu-
tation in three MLASA patients (P1, P2 and P3; Table 1)
who demonstrated a muscle-specific RC deficiency af-
fecting complexes I, III and IV [16]. Screening of two
additional unrelated patients with similar clinical features
identified Patients P4 and P5 as also being homozygous
for the missense mutation c.156C >G (p.Phe52Leu). The
non-consanguineous parents of P4 showed both were het-
erozygous for the c.156C >G substitution. Parental DNA
was not available for P5.
Despite similar RC enzyme results in muscle, clinical
severity varied greatly among patients (Table 1). Patient
P4 showed a severe phenotype and died at 3 months due
to hypertrophic cardiomyopathy. P1 also had cardio-
myopathy in infancy, however this resolved without
specific therapy. P5 did not develop symptoms until adult-
hood, characterised by mild myopathy and transfusion-
independent anaemia. Patient P2 presented at birth with a
moderate myopathy and transfusion-dependent anaemia.
Remarkably, at 17 years of age her clinical condition spon-
taneously improved, while her sibling, P1, had progressive
muscle weakness, becoming wheelchair bound by 14 years
and died of respiratory failure at 18 years of age. The four
older YARS2 p.Phe52Leu patients all had normal cognitive
function. All five of the homozygous p.Phe52Leu YARS2
patients are Australians of Lebanese origin consistent with
our proposal that p.Phe52Leu represents a rare founder
mutation [16].
mtDNA sequencing revealed that although the pa-
tients were of the same ethnicity, they did not all have
the same mtDNA haplogroup (Table 1; see Additional
file 2 for a complete list of mtDNA variations). The 3
previously reported patients (P1,P2 & P3) all belonged
to haplogroup K. P4, the most severely affected patient,
belonged to haplogroup T and P5, the least severely af-
fected patient belonged to haplogroup H.
Table 1 Clinical data for YARS2 patients
Patient P1 P2a P3 P4 P5 P6
YARS2 variant [c.156C > G];
[c.156C > G]
[p.Phe52Leu];
[p.Phe52Leu]
[c.156C > G];
[c.156C > G]
[p.Phe52Leu];
[p.Phe52Leu]
[c.156C > G];
[c.156C > G]
[p.Phe52Leu];
[p.Phe52Leu]
[c.156C > G];
[c.156C > G]
[p.Phe52Leu];
[p.Phe52Leu]
[c.156C > G];
[c.156C > G]
[p.Phe52Leu];
[p.Phe52Leu]
[c.572G > A];
[c.1078C > T]
[p.Gly191Asp];
[p.Arg360X]
mtDNA haplogroup K1a4f1 K1 K1a4f T1a8 H ND
RC Enzyme Activityb Muscle Fibroblast Muscle Fibroblast Muscle Fibroblast Muscle Liver Muscle Fibroblast Muscle Lymphocyte
Complex I/CS 8 62 3 ND 25 80 2 49 ND ND ND 85
Complex II/CS 150 116 139 ND 110 39 132 191 ND ND ND 94
Complex III/CS ND 107 3 ND ND 56 4 105 ND ND ND 67
Complex IV/CS 12 89 2 ND 7 52 3 85 ND ND ND 70
CSc 236 67 319 ND 94 94 376 254 ND ND ND 319
Sideroblastic anaemia Severe Moderate Mild Severe Mild Mild
Transfusion
dependent from
birth
Transfusion
dependent from
birth to 17 y
From 7 y Transfusion
dependent from
birth
From 23 y Transfusion dependent
during first year
Not transfused for
personal reasons
Not transfusion
dependent
Hb 70–110 g/L Hb 42 g/L Hb 104 g/L
Lactic acidosis Severe Moderate Mild Severe Mild Mild
3–13.7 mmol/L 2.5-8.4 mmol/L 4.1 mmol/L 27 mmol/L 3.24-5.10 mmol/L 2–3 mmol/L
Myopathy Severe Moderate Mild ND Mild Mild
Other features Cardiomyopathy
in infancy
Currently 20 y with
improvement in
clinical features
Currently 27 y Cardiomyopathy Currently 28 y Currently 6 y
Deceased at 18 y Deceased at 3
mo
aSibling of P1.
bValues expressed as % residual activity.
cCitrate synthase activity was expressed relative to protein.
CS = citrate synthase.
ND = not determined.
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YARS2 screening identifies new mutations
YARS2 and PUS1 mutation screening was performed on a
cohort of ten French or Italian patients with demonstrated
RC enzyme deficiency who also presented with anaemia
and at least one of the other MLASA features, ie. lactic
acidosis or myopathy. One patient, P6 (Table 1) had two
novel YARS2 mutations, a heterozygous missense mutation
c.572G >A (p.Gly191Asp) and a heterozygous nonsense
mutation c.1078C > T (p.Arg360X). Patient P6 YARS2 vari-
ations were not present in dbSNP (NCBI), 1000 genomes
(browser.1000genomes.org), or the ESP database (evs.gs.
washington.edu). Screening of parental DNA showed that
each parent carried one or the other of the mutations.
Patient P6 ([p.Gly191Asp];[p.Arg360X]) has mild lactic
acidosis and myopathy, and only required blood transfu-
sions during the first year of life (Table 1). Impaired
complex IV enzymology was demonstrated via RC test-
ing of lymphocytes and defective assembly of complexes
I, III, IV & V on Blue Native-PAGE of fibroblast samples
(data not shown).
YARS2 variants were identified in two other patients
(P7 & P8) however they are unlikely to be pathogenic.
These are described in Additional file 1. No PUS1 muta-
tions were identified in this cohort of patients.
p.Gly191Asp YARS2 displays reduced aminoacylation
activity
To determine the functional impact of the p.Gly191Asp
YARS2 mutation on tyrosylation capacity, in vitro assays
were performed using E. coli tRNATyr as substrate.
Gly191 lies within the catalytic domain of YARS2 [24],
and the protein prediction program SIFT (http://sift.jcvi.
org/) predicts the Gly191Asp variation to be damaging.
The aminoacylation assay measured incorporation of
[14C]-tyrosine on native E. coli tRNATyr by recombinant
YARS2. The p.Gly191Asp mutation did not significantly
affect the Km of the reaction (Table 2), indicating that
YARS2 interaction with tRNATyr was apparently un-
affected. However the catalytic rate (kcat) was perturbed,
resulting in reduced tyrosylation activity. The p.Gly191Asp
variant resulted in a 38-fold decrease in catalytic efficiency
(kcat / Km) as compared to the wild-type enzyme, a greater
reduction than the previously reported p.Phe52Leu muta-
tion (9-fold decrease) [16]. This result was consistent with
the SIFT prediction of the severity of the p.Gly191Asp
variation on protein function.
YARS2 protein levels are unaffected while RC complex
expression levels are altered
The expression level of YARS2 and the RC complexes was
investigated by immunoblotting of patient P6 fibroblast
and myotubes (Figure 1a). Due to the muscle-specific na-
ture of the YARS2 RC deficiency and the unavailability of
P6 muscle samples, myotubes were generated by transdif-
ferentiation of fibroblasts using a lentiviral vector express-
ing MyoD [21], a master regulatory myogenic transcription
factor. This model was validated by demonstrating a si-
milar induction of mitochondrial RC expression levels via
native and Myo-D forced myogenesis for patient P2, for
whom a myoblast cell line was available (Additional file 3).
Protein levels of YARS2 were not significantly altered in ei-
ther patient P6 fibroblasts or MyoD-forced myotubes, rela-
tive to controls, suggesting that reduced YARS2 protein
levels are not the cause of the muscle-specific phenotype.
This was also the case for p.Phe52Leu YARS2 (P2), which
is shown for comparison (Figure 1a). There was no evi-
dence of a truncated YARS2 protein that might be ex-
pected to arise from the p.Arg360X mutation in P6.
Sequencing of P6 cDNA showed that the c.1078C > T (p.
Arg360X) mutant transcript was unstable and qPCR
showed that total YARS2 mRNA levels were ~50% of con-
trols (Additional file 4). Porin (VDAC), an outer mitochon-
drial membrane protein, and α-actinin-2, a muscle specific
protein, were used as loading controls, and to demonstrate
the efficacy of the transdifferentiation of fibroblasts into
myotubes (Figure 1a). Immunoblotting of patient fibroblast
samples showed RC complex I & IV levels were 50-60% of
control levels (Figure 1a). The observed complex I & IV
deficiencies were more severe in MyoD-forced myotubes
(P2:25-50% of control levels; P6:5-10% of control levels)
compared to fibroblasts, consistent with a muscle-specific
phenotype.
RC deficiency is more severe in muscle cells
We measured complex IV activity in myotubes derived from
MyoD-forced myogenesis of fibroblasts from YARS2 pa-
tients P2 (p.Phe52Leu) and P6 ([p.Gly191Asp];[p.Arg360X)
to confirm that the reduced RC complex levels (Figure 1a)
correlated with a reduction in RC enzyme activity. Trans-
differentiation of fibroblasts to myotubes resulted in a
significant increase in complex IV activity relative to total
protein in normal controls (P = 0.002; Figure 1b), consistent
with the increased relative levels of mitochondrial RC sub-
units detected by Western blot (Figure 1a and Additional
file 3). In contrast, for both the patient P2 & P6 cell lines
there was a decrease in complex IV activity relative to total
protein (P < 0.001; Figure 1b) and relative to citrate syn-
thase (P ≤ 0.005; Figure 1c). Both patient P2 fibroblasts and
patient P6 fibroblasts had significantly lower complex IV/
CS activity compared to control fibroblasts (P = 0.02 and
P < 0.001 respectively; Figure 1c). However, MyoD-forced
Table 2 Kinetic parameters for tyrosylation of tRNATyr by
wild-type and p.Gly191Asp YARS2 recombinant proteins
YARS2
Variant
Km
(μM)
kcat
(min-1)
kcat/Km
(Efficiency)
Loss of Efficiencya
(Fold change)
WT 1 34 34 1
p.Gly191Asp 1 0.9 0.9 38
aLoss of efficiency is calculated relative to the wild-type YARS2.
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myogenesis revealed a deficit in Complex IV/CS activity
that was < 50% of control levels and could be considered
diagnostic. These results were consistent with the more
severely reduced levels of Complex IV observed in pa-
tient myotubes compared to fibroblasts by Western blot
(Figure 1a).
The muscle-specific phenotype of YARS2 patients may
be related to the increased requirements for RC com-
plexes in muscle [25,26]. Thus, we compared the relative
levels of mitochondrial RC expression levels in 10 μg of
total protein from fibroblasts, MyoD-forced myotubes,
and skeletal muscle (Figure 2). In control samples, there
was a ~2-fold increase in the relative levels of all RC
complexes with transdifferentiation from fibroblasts to
myotubes, and a further ~2-fold incremental increase of
RC expression levels between myotubes and skeletal
myofibres (Figure 2). However, cells from Patient 2 failed
to induce mitochondrial RC complex I and IV expres-
sion with myogenesis, either via forced myogenesis of fi-
broblasts (Figure 2) or indeed native myogenesis of
myoblasts (Additional file 3). Skeletal muscle samples from
Figure 1 RC complex deficiency is more severe in muscle cells. Immunoblot of RC complex and YARS2 levels in YARS2 patient fibroblasts
and MyoD-forced myotubes (A). C = control, P2 = [p.Phe52Leu];[p.Phe52Leu] YARS2, P6 = [p.Gly191Asp];[p.Arg360X] YARS2. Complex IV activity
was measured relative to total protein (B) and citrate synthase activity (C) in control (C) and patients (P2 & P6) fibroblasts (Fib) and MyoD-forced
myotubes (Myo). Experiments were performed at least twice, in triplicate each time. Control fibroblasts were normalised to 100%. Values are
the mean ± SD.
Figure 2 RC complex levels are dysregulated on myogenesis in
patient muscle cells. Control (C) MyoD-forced myotubes (Myo) and
muscle (Musc) have higher RC complex levels than fibroblasts (Fib)
while patient (P2) MyoD-forced myotubes and muscle are deficient
in Complex I (CoI NDUFB8), and IV (CoIV II).
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Patient 2 demonstrated a severe deficiency of complex I
and IV, with compensatory upregulation of complex II.
Thus, our results suggest that patients with YARS2 muta-
tions can generate sufficient RC complex I, and IV in fibro-
blasts, but not in muscle where there is increased demand.
There were higher levels of mitofilin and porin (VDAC)
in control myotubes and muscle compared to fibroblasts,
indicative of greater numbers (or size) of mitochondria with
myogenesis (Figure 2); consistent with increased RC com-
plex levels. Skeletal muscle from patient P2 showed higher
levels of mitofilin and porin compared to control muscle,
suggesting mitochondrial proliferation was upregulated in
response to the RC deficiency. There was no evidence of a
compensatory upregulation of YARS2 in patient muscle.
Mitochondrial biogenesis is altered in patient muscle cells
We further investigated the role of mitochondrial prolifer-
ation in YARS2 pathology. PGC1-α is a transcription co-
activator which promotes mitochondrial biogenesis [27]
and TFAM controls mtDNA copy number and transcrip-
tion [28]. Elevated levels of PGC1-α and TFAM were seen
in patient P2 muscle compared to controls (Figure 3a),
consistent with induction of mitochondrial proliferation
pathways. Interestingly, relative levels of mtDNA/nDNA
were not significantly higher in patient P2 muscle com-
pared to control muscle (P = 0.09; Figure 3c), despite our
biochemical evidence showing higher relative levels of
mitochondrial structural proteins and induction of PGC1-
α and TFAM pathways.
We next assessed the relative levels of PGC1-α and
TFAM with myogenesis in patient and control myoblasts.
PGC1-α levels were similar in patient and control myo-
blasts and myotubes, and showed ~2-fold upregulation
with myogenesis (Figure 3b). Levels of TFAM also in-
creased incrementally with myogenesis, but showed 3-fold
higher expression levels in patient myoblasts and myo-
tubes, relative to controls (Figure 3b). Analysis of the rela-
tive levels of mtDNA/nDNA during myogenesis showed
there was strong evidence of an interaction between cell
type and sample (P < 0.001) so cell types were compared
within samples. Myogenesis of control myoblasts induced
a ~2-fold increase in the relative levels of mtDNA/nDNA
(P < 0.001). However, myogenesis-induced upregulation of
mtDNA proliferation was not observed for P2 (P = 0.22;
Figure 3d). The elevated level of TFAM observed in pa-
tient muscle tissue and cells, does not appear to result in
elevated mtDNA levels.
Discussion
Here we refine the clinical spectrum associated with
YARS2 mutations through mutation screening of a cohort
of mitochondrial RC disorder patients with anaemia. Five
patients from four families homozygous for the p.Phe52-
Leu substitution are now identified, revealing marked clin-
ical variability in age of onset and severity of sideroblastic
anaemia and myopathy. We hypothesize that the mtDNA
background may contribute to the observed clinical va-
riability among patients. P4, the most severely affected
Figure 3 Mitochondrial biogenesis is altered in patient muscle cells. Immunoblot of RC complex, PGC1-α, and TFAM levels in control (C) and
patient P2 muscle (Musc) (A), myoblasts (Myb) and myotubes (Myt) (B). α-actinin-2 levels are shown as a loading control for muscle and as an
indicator of myogenesis in myotubes. Mitochondrial DNA copy number was determined by qPCR in control (C) and patient (P2) muscle (C) and
myoblasts and myotubes (D). Experiments were performed twice, in triplicate each time. Results are expressed relative to a control muscle (C) or
myoblast (D) value of 1. Values are the mean ± SD. ns = not significantly different.
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patient who died in infancy due to hypertrophic cardiomy-
opathy, belonged to haplogroup T. Haplogroup T has
been associated with risk of developing hypertrophic car-
diomyopathy [29], and is less frequent among elite endur-
ance athletes, and is indicative of decreased mitochondrial
capacity of this haplogroup [30]. Patient P5, the least se-
verely affected, belonged to haplogroup H. Mitochondrial
protein synthesis levels were higher in cybrids from hap-
logroup H compared to haplogroups U (of which hap-
logroup K is a subclade) [31] and J [32]. Thus haplogroup
H may offer some protection against the effects of the
YARS2 mutation which causes reduced mitochondrial
protein synthesis. The remaining 3 patients, who also
showed differences in disease severity, were all haplogroup
K which suggests that there may be additional factors that
affect disease severity. All patients were Australian-born
of Lebanese origin from four unrelated families consistent
with p.Phe52Leu being a founder mutation [16]. Recently,
a p.Gly46Asp YARS2 mutation was reported to cause
similar clinical features, ie muscle-specific RC deficien-
cies of complexes I, III & IV in a MLASA patient, also
of Lebanese origin [33]. Hence patients of Lebanese origin
presenting with MLASA symptoms at any age should be
screened for YARS2 mutations.
A patient with anaemia within the first year of life and
mild lactic acidosis and myopathy was found to be com-
pound heterozygous for two novel YARS2 mutations,
p.Gly191Asp and p.Arg360X. Gly191 is located within
the catalytic domain of YARS2, just before cluster 1,
which is known to interact with base-pair 1–72 of the
tRNATyr acceptor stem [24]. A mutation at this location
may disturb positioning of the α-helix of cluster 1, and
hence adversely affect the aminoacylation reaction. This
was confirmed by in vitro aminoacylation assay of a
recombinant p.Gly191Asp YARS2, which displayed a
38-fold loss in catalytic efficiency compared to the
wild-type enzyme, and is predicted to result in reduced
mitochondrial protein synthesis, as was seen with the
p.Phe52Leu mutation [16]. The mRNA transcript pro-
duced from the c.1078C > T (p.Arg360X) YARS2 mutant
was unstable and is most likely degraded by nonsense me-
diated decay due to the proximity of the mutation to an
intron/exon boundary. There was no evidence of a trun-
cated p.R360X YARS2 protein using an antibody targeted
to the N-terminus of YARS2. Patient P6 YARS2 protein
levels were maintained however, this is the less functional
p.Gly191Asp YARS2. We consider that the mitochondrial
RC disorder in patient P6 is a result of the combined effect
of the p.Gly191Asp and p.Arg360X YARS2 mutations.
We did not identify pathogenic YARS2 or PUS1 muta-
tions in the remaining nine patients, none of who had all
the clinical features seen in those with pathogenic YARS2
mutations (Additional file 1). Common features in patients
with pathogenic YARS2 mutations are enzyme deficiencies
of complexes I, III and IV in muscle, sideroblastic anaemia
(although onset and duration may vary between patients),
lactic acidosis, and skeletal myopathy and/or cardiomyop-
athy. However, it is possible that YARS2 mutations may be
identified in RC disorder patients with alternate pheno-
types in future, as our cohort was selected based on pres-
ence of anaemia.
The basis for the muscle-specific manifestation of RC
complex deficiencies in YARS2 patients appears due to an
increased requirement for OXPHOS components in
muscle compared to fibroblasts or myoblasts. Upon myo-
genesis, mitochondrial proliferation occurs, resulting in in-
creased levels of RC complexes and mtDNA/nDNA [25],
as we observed in control myoblasts. However, YARS2
patient cells were unable to induce sufficient expression
of RC complex I, III and IV levels with myogenesis.
Levels of porin and mitofilin increased, suggesting mito-
chondrial proliferation occurs, however YARS2 patient
cells are unable to synthesise sufficient levels of mito-
chondrially encoded subunits of the RC complexes due
to the defective aminoacylation activity of the mutant
YARS2. This defect impacts mtDNA proliferation with
myogenesis, possibly due to reduced intramitochondrial
ATP levels, as high ATP concentrations are required for
mtDNA transcription [34]. mtDNA transcription is a
prerequisite for mtDNA replication, and mtDNA tran-
scription and translation are also closely linked [35].
Muscle mitochondrial content is established during dif-
ferentiation and development, and then maintained or
modified throughout life [36]. The level of mtDNA/nDNA
in muscle from P2 was comparable to controls, suggesting
that over time, mitochondrial proliferation may have oc-
curred as a compensatory response to the mitochondrial
RC deficiency. The increased levels of PGC1-α and TFAM
observed in patient muscle compared to controls are con-
sistent with this hypothesis. In addition, in recently per-
formed transcription profiling of P2 muscle before and
after clinical improvement, mRNA levels for TFAM and
PGC1-α were significantly higher than controls when the
patient was displaying severe clinical features and returned
to normal upon clinical improvement (data not shown).
The elevated TFAM and PGC1-α protein levels with myo-
genesis are consistent with initiation of mitochondrial
proliferation and suggest pressure on mitochondrial pro-
liferative pathways as a consequence of low mtDNA copy
number. Hence, it is possible that the defective translation
caused by YARS2 mutations, which results in mitochon-
drial RC dysfunction and decreased ATP production, also
affects mtDNA transcription and replication, compound-
ing the RC defect.
In conclusion, we have found that a homozygous YARS2
p.Phe52Leu mutation is a frequent cause of MLASA
among patients of Lebanese origin, with patients displaying
both inter- and intra-familial phenotypic variability. We
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have also identified a patient compound heterozygous for
two novel YARS2 mutations (p.Gly191Asp and p.Arg360X).
We refine the clinical hallmarks of YARS2 pathology to in-
clude muscle-specific defects in complexes I, III and IV,
with sideroblastic anaemia and skeletal myopathy and/or
cardiomyopathy. The tissue-specific effects of YARS2 disor-
ders are related to the higher requirement for OXPHOS
components in muscle. Further studies, including transcrip-
tomic studies, may help reveal the compensatory mecha-
nisms that are activated in response to the YARS2-induced
RC dysfunction.
Additional files
Additional file 1: Clinical features of patients who did not have a
pathogenic YARS2 mutation. Clinical features are described for the
patients who did not have a pathogenic YARS2 mutation. Non-pathogenic
YARS2 variants were identified in patients 7 and 8. Aminoacylation data
for the variants shows they only have mild effects and probably are not
pathogenic.
Additional file 2: mtDNA variations in p.Phe52Leu YARS2 patients.
mtDNA variations and their effects are shown for each of the p.Phe52Leu
YARS2 patients. Novel variations are highlighted in blue.
Additional file 3: Comparison of native and MyoD forced
myogenesis. Transdifferentiation of fibroblasts (Fib) to myotubes (Myo)
using a MyoD lentiviral vector (Myo-D forced myogenesis) gives rise to
similar RC complex and YARS2 expression levels as seen in native in vitro
myogenesis, involving differentiation of myoblasts (Myb) to myotubes
(Myt), in both control (C) and patient (P2) cell lines.
Additional file 4: YARS2 mRNA levels in Patient P6. Sequencing
chromatograms of P6 gDNA (A) and cDNA (B) showing the heterozygous
c.1078C > T (p.Arg360X) mutation. The mutant transcript is less abundant
than the wild-type, demonstrated by the lower peak height of the
mutant “T” in the cDNA (B) compared to the wild-type “C”. Total YARS2
mRNA level in P6 was ~50% of control levels (C). YARS2 mRNA level was
determined by qPCR and normalised to mRNA level of a housekeeping
gene, RPL13A. Results are presented as mean fold change relative to
control +/− SD (n ≥ 4).
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